Merrimack Pharmaceuticals to Present at Oppenheimer 25th Annual Healthcare Conference, Hold Analyst Day and Present Research on Multiple Molecules in December 2014
December 01, 2014 16:01 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced it will present at three events during the month of December.
Oppenheimer 25th...
Merrimack Pharmaceuticals Presents on Multiple Programs at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
November 21, 2014 08:00 ET
|
Merrimack Pharmaceuticals
Clinical data from Phase 1 studies of MM-398 and MM-151 presented
First public presentation of MM-131, a novel bi-specific antibody targeting the c-Met signaling pathway
BARCELONA, Spain, Nov....
Merrimack Pharmaceuticals Receives FDA Fast Track Designation for MM-398 in Post-Gemcitabine Metastatic Pancreatic Cancer
November 19, 2014 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Nov. 19, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the U.S. Food and Drug Administration (FDA) has granted MM-398 (nanoliposomal...
Photo Release -- Merrimack Pharmaceuticals Announces the Addition of Vivian S. Lee, Dean of University of Utah School of Medicine, to Its Board of Directors
November 17, 2014 08:30 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the election of Vivian S. Lee, Ph.D., M.D., M.B.A. to its Board of Directors. Lee...
Merrimack Pharmaceuticals to Present Advances on Targeted Cancer Molecules at the 2014 EORTC-NCI-AACR Symposium
November 13, 2014 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will present research on three of its therapeutic candidates at the 2014...
Merrimack Pharmaceuticals Reports Third Quarter 2014 Financial Results
November 10, 2014 16:01 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative...
Merrimack Pharmaceuticals Announces Initiation of Phase 1 Clinical Study of MM-398 for Brain Cancer
November 06, 2014 08:30 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the first patient has been enrolled in a Phase 1 clinical study of MM-398...
FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals' MM-141 for the Treatment of Pancreatic Cancer
November 05, 2014 09:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to...
Merrimack Pharmaceuticals Announces Timing of Third Quarter 2014 Investor Conference Call
November 03, 2014 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Third Quarter 2014 Investor Conference Call and webcast...
Merrimack Pharmaceuticals Presents Additional Phase 2 Biomarker Data Further Strengthening the Finding That MM-121 Increases Progression Free Survival in Patients With Biomarker Positive Metastatic Breast Cancer
September 30, 2014 08:00 ET
|
Merrimack Pharmaceuticals
Data Presented as Part of Meta-Analysis Showing MM-121's Favorable Impact on Progression Free Survival in 38-54 Percent of Patients With Ovarian, Lung and Breast Cancers Across Three Phase 2...